IMHA in Canine (Small Breeds)

Understand the challenges of Immune-Mediated Haemolytic Anaemia (IMHA) in Small-Breed Dogs in this in-depth presentation by Prof. Dr. Mike Chan, tailored for veterinarians, canine internal medicine experts, and devoted pet owners. IMHA is a severe autoimmune condition in which the body’s immune system targets and destroys its own red blood cells, resulting in anaemia, jaundice, and possible multi-organ complications. It may arise from unknown immune dysregulation or be triggered by infections, neoplasia, or adverse drug reactions. Early signs can include weakness, pale or yellow-tinged gums, rapid breathing, dark urine, and loss of appetite. Diagnosis typically combines blood analysis, reticulocyte counts, biochemical profiling, and tests for infectious agents. Treatment follows a comprehensive plan—blending immediate medical stabilisation, immune-modulating therapy, and careful follow-up with regenerative strategies such as PSC (Precursor Stem Cell Therapy), FOP (Frozen Organo Peptides), FOC (Frozen Organo Cryogenics), and advanced TopPetPro innovations like MITO Peptide Organotherapy, NANO Peptide Organotherapy, etc.—to control immune activity, stimulate red blood cell production, and support recovery.